$3.82
0.051.33%
Last update: Nov 3, 9:26 AM
Aquestive Therapeutics Inc
AQSTNASDAQ
Aquestive Therapeutics (AQST) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Aquestive Therapeutics (AQST) last issued guidance on August 11, 2026 for fiscal year 2026. The company guided revenue in the range of $46M - $50M for the period.
Compared to prior guidance, Aquestive Therapeutics maintained its revenue forecast from a prior range of $46M - $50M.
Aquestive Therapeutics has issued 16 guidance updates between March 7, 2023 and August 11, 2026. During this period, the company raised its outlook 6 times and lowered it 2 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.13 | $-0.12 | $-0.13 | $-0.12 |
| Actual | — | $-0.18 | $-0.07 | $-0.15 |
| Surprise | — | -50.0% | +46.2% | -25.0% |
| Revenue | ||||
| Estimate | $11.0M | $11.7M | $10.9M | $13.3M |
| Actual | — | $13.8M | $14.4M | $13.0M |
| Surprise | — | +18.1% | +32.7% | -2.28% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|
| Earnings Per Share (Non-GAAP) | |||
| Consensus | $-0.13 | $-0.09 | $-0.10 |
| Revenue | |||
| Consensus | $11.6M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $-0.18 | $-0.12 | -50.0 % |
| Q1 | May 13, 2026 | $-0.07 | $-0.13 | 46.2 % |
| Q4 | Mar 4, 2026 | $-0.15 | $-0.12 | -25.0 % |
| Q3 | Nov 5, 2025 | $-0.14 | $-0.12 | -16.7 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q2 | Aug 11, 2026 | $13.82M | $11.70M | 18.1 % |
| Q1 | May 13, 2026 | $14.45M | $10.88M | 32.7 % |
| Q4 | Mar 4, 2026 | $13.02M | $13.32M | -2.28 % |
| Q3 | Nov 5, 2025 | $12.81M | $13.11M | -2.31 % |
